For example, predicting the response to trastuzumab in breast cancer patients is dictated by positivity to HER2 [6–8], sensitivity to the anti-EGFR inhibitor gefitinib in NSCLC patients is predicted by EGFR mutations [9, 10] and resistance to the anti-EGFR monoclonal antibody cetuximab in advanced colorectal cancer patients is predicted by KRAS mutations [11]. This evidence concerns the gene EGFR and breast carcinoma.